Roche Holding AG (OTCMKTS:RHHBY) Shares Sold by John G Ullman & Associates Inc.

John G Ullman & Associates Inc. trimmed its position in shares of Roche Holding AG (OTCMKTS:RHHBY) by 7.8% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 7,100 shares of the company’s stock after selling 600 shares during the quarter. John G Ullman & Associates Inc.’s holdings in Roche were worth $284,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. AlphaMark Advisors LLC purchased a new stake in shares of Roche during the 3rd quarter valued at about $149,000. GAMMA Investing LLC increased its holdings in shares of Roche by 61.5% in the 2nd quarter. GAMMA Investing LLC now owns 5,038 shares of the company’s stock valued at $175,000 after purchasing an additional 1,919 shares during the period. Verity Asset Management Inc. acquired a new stake in shares of Roche during the 3rd quarter valued at $253,000. Archer Investment Corp grew its stake in Roche by 10.6% in the second quarter. Archer Investment Corp now owns 6,810 shares of the company’s stock valued at $236,000 after purchasing an additional 652 shares in the last quarter. Finally, Waldron Private Wealth LLC bought a new stake in Roche in the second quarter worth approximately $263,000.

Roche Trading Up 0.5 %

Shares of Roche stock opened at $35.29 on Friday. Roche Holding AG has a 12-month low of $29.20 and a 12-month high of $42.43. The firm’s 50-day moving average price is $38.68 and its two-hundred day moving average price is $37.23.

Analyst Ratings Changes

RHHBY has been the topic of several recent research reports. Bank of America upgraded shares of Roche from a “neutral” rating to a “buy” rating in a research report on Friday, September 13th. Deutsche Bank Aktiengesellschaft cut Roche from a “hold” rating to a “sell” rating in a research note on Friday, September 13th. Three equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold”.

Roche Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.